Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.

Neves JS, Leite AR, Mentz RJ, Holman RR, Zannad F, Butler J, Packer M, Ferreira JP

European journal of heart failure9 Oct 2024Cited by 26 (Europe PMC)

PMID39381950DOI10.1002/ejhf.3478PepBankPUB-39381950

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanOther designEfficacy outcome
In T2D, baseline LVEF modified the exenatide effect on HHF versus placebo.
In plain wordsIn T2D, exenatide's effect on heart failure hospitalization versus placebo differed by baseline ejection fraction.
Peptide
Exenatide (exendin-4)
Outcome
MixedLVEF interaction for heart failure hospitalization
Study
n = 4,749
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
once weeklyAs given in this study (human).
Measurements
p-interaction
0.012 p-value
treatment-by-LVEF interaction for HHF
Source sentences
Summary
LVEF modified the EQW effect on hHF: hazard ratio (HR) = 1.52 (95% confidence interval [CI] = 0.95-2.43) in participants with LVEF < 40% and HR = 0.74 (95% CI = 0.55-1.01) in those with LVEF ≥ 40% (p-interaction = 0.012).
3 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analysis of the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial evaluating the effects of once-weekly exenatide (EQW) versus placebo on cardiovascular outcomes according to baseline LVEF (<40% or ≥40%).
Summary · context
The main outcome was hospitalization for heart failure (HHF).
Summary · context
In EXSCEL (n = 14 752), 4749 participants had LVEF available at baseline; 455 (10%) with LVEF <40%, 4294 (90%) with LVEF ≥40%.
Report a problemFND-3938195003
02HumanOther designEfficacy outcome
In T2D with LVEF ≥40%, exenatide had an HHF hazard ratio of 0.74 versus placebo, with confidence intervals including no effect.
In plain wordsIn T2D with higher ejection fraction, exenatide did not significantly change heart failure hospitalization risk versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHeart failure hospitalization, LVEF ≥40%
Study
n = 4,294
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
once weeklyAs given in this study (human).
Measurements
HHF hazard ratio
0.74 ratio
LVEF ≥40%
95% CI lower
0.55 ratio
LVEF ≥40%
95% CI upper
1.01 ratio
LVEF ≥40%
Source sentences
Summary
LVEF modified the EQW effect on hHF: hazard ratio (HR) = 1.52 (95% confidence interval [CI] = 0.95-2.43) in participants with LVEF < 40% and HR = 0.74 (95% CI = 0.55-1.01) in those with LVEF ≥ 40% (p-interaction = 0.012).
3 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analysis of the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial evaluating the effects of once-weekly exenatide (EQW) versus placebo on cardiovascular outcomes according to baseline LVEF (<40% or ≥40%).
Summary · context
The main outcome was hospitalization for heart failure (HHF).
Summary · context
In EXSCEL (n = 14 752), 4749 participants had LVEF available at baseline; 455 (10%) with LVEF <40%, 4294 (90%) with LVEF ≥40%.
Report a problemFND-3938195002
03HumanOther designEfficacy outcome
In T2D with LVEF <40%, exenatide had an HHF hazard ratio of 1.52 versus placebo, with confidence intervals including no effect.
In plain wordsIn T2D with low ejection fraction, exenatide did not significantly change heart failure hospitalization risk versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHeart failure hospitalization, LVEF <40%
Study
n = 455
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
once weeklyAs given in this study (human).
Measurements
HHF hazard ratio
1.52 ratio
LVEF <40%
95% CI lower
0.95 ratio
LVEF <40%
95% CI upper
2.43 ratio
LVEF <40%
Source sentences
Summary
LVEF modified the EQW effect on hHF: hazard ratio (HR) = 1.52 (95% confidence interval [CI] = 0.95-2.43) in participants with LVEF < 40% and HR = 0.74 (95% CI = 0.55-1.01) in those with LVEF ≥ 40% (p-interaction = 0.012).
3 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analysis of the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial evaluating the effects of once-weekly exenatide (EQW) versus placebo on cardiovascular outcomes according to baseline LVEF (<40% or ≥40%).
Summary · context
The main outcome was hospitalization for heart failure (HHF).
Summary · context
In EXSCEL (n = 14 752), 4749 participants had LVEF available at baseline; 455 (10%) with LVEF <40%, 4294 (90%) with LVEF ≥40%.
Report a problemFND-3938195001
04HumanOther designEfficacy outcome
In T2D, LVEF did not significantly modify the exenatide effect on MACE versus placebo.
In plain wordsIn T2D, exenatide's effect on major cardiovascular events versus placebo did not significantly differ by ejection fraction.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeLVEF interaction for MACE
Study
n = 4,749
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
once weeklyAs given in this study (human).
Measurements
p-interaction
> 0.1 p-value
treatment-by-LVEF interaction for MACE
Source sentences
Summary
No significant treatment-by-LVEF interactions (p-interaction >0.10) were observed for MACE, cardiovascular death or all-cause mortality.
2 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analysis of the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial evaluating the effects of once-weekly exenatide (EQW) versus placebo on cardiovascular outcomes according to baseline LVEF (<40% or ≥40%).
Summary · context
In EXSCEL (n = 14 752), 4749 participants had LVEF available at baseline; 455 (10%) with LVEF <40%, 4294 (90%) with LVEF ≥40%.
Report a problemFND-3938195004
05HumanOther designEfficacy outcome
In T2D, LVEF did not significantly modify the exenatide effect on cardiovascular death versus placebo.
In plain wordsIn T2D, exenatide's effect on cardiovascular death versus placebo did not significantly differ by ejection fraction.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeLVEF interaction for cardiovascular death
Study
n = 4,749
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
once weeklyAs given in this study (human).
Measurements
p-interaction
> 0.1 p-value
treatment-by-LVEF interaction for cardiovascular death
Source sentences
Summary
No significant treatment-by-LVEF interactions (p-interaction >0.10) were observed for MACE, cardiovascular death or all-cause mortality.
2 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analysis of the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial evaluating the effects of once-weekly exenatide (EQW) versus placebo on cardiovascular outcomes according to baseline LVEF (<40% or ≥40%).
Summary · context
In EXSCEL (n = 14 752), 4749 participants had LVEF available at baseline; 455 (10%) with LVEF <40%, 4294 (90%) with LVEF ≥40%.
Report a problemFND-3938195005
06HumanOther designEfficacy outcome
In T2D, LVEF did not significantly modify the exenatide effect on all-cause mortality versus placebo.
In plain wordsIn T2D, exenatide's effect on death from any cause versus placebo did not significantly differ by ejection fraction.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeLVEF interaction for all-cause mortality
Study
n = 4,749
Comparator
Placebo
Outcome group
Mortality · Cardiovascular
Studied dose
once weeklyAs given in this study (human).
Measurements
p-interaction
> 0.1 p-value
treatment-by-LVEF interaction for all-cause mortality
Source sentences
Summary
No significant treatment-by-LVEF interactions (p-interaction >0.10) were observed for MACE, cardiovascular death or all-cause mortality.
2 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analysis of the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial evaluating the effects of once-weekly exenatide (EQW) versus placebo on cardiovascular outcomes according to baseline LVEF (<40% or ≥40%).
Summary · context
In EXSCEL (n = 14 752), 4749 participants had LVEF available at baseline; 455 (10%) with LVEF <40%, 4294 (90%) with LVEF ≥40%.
Report a problemFND-3938195006
07HumanOther designEfficacy outcome
In T2D with NYHA class I/II, exenatide had an HHF hazard ratio of 0.91 versus placebo, with confidence intervals including no effect.
In plain wordsIn T2D with NYHA class I/II, exenatide did not significantly change heart failure hospitalization risk versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHeart failure hospitalization, NYHA I/II
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
once weeklyAs given in this study (human).
Measurements
HHF hazard ratio
0.91 ratio
NYHA class I/II
95% CI lower
0.65 ratio
NYHA class I/II
95% CI upper
1.27 ratio
NYHA class I/II
Source sentences
Summary
The risk of HHF was also modified by baseline NYHA class (HR 0.91, 95% CI 0.65-1.27 for NYHA class I/II; HR 1.84, 95% CI 0.95-3.59 for NYHA class III/IV; p-interaction = 0.062), mostly driven by the LVEF <40% subgroup.
1 context sentence(design, population, supporting numbers)
Summary · context
Post-hoc analysis of the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial evaluating the effects of once-weekly exenatide (EQW) versus placebo on cardiovascular outcomes according to baseline LVEF (<40% or ≥40%).
Report a problemFND-3938195007
08HumanOther designEfficacy outcome
In T2D with NYHA class III/IV, exenatide had an HHF hazard ratio of 1.84 versus placebo, with confidence intervals including no effect.
In plain wordsIn T2D with NYHA class III/IV, exenatide did not significantly change heart failure hospitalization risk versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHeart failure hospitalization, NYHA III/IV
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
once weeklyAs given in this study (human).
Measurements
HHF hazard ratio
1.84 ratio
NYHA class III/IV
95% CI lower
0.95 ratio
NYHA class III/IV
95% CI upper
3.59 ratio
NYHA class III/IV
Source sentences
Summary
The risk of HHF was also modified by baseline NYHA class (HR 0.91, 95% CI 0.65-1.27 for NYHA class I/II; HR 1.84, 95% CI 0.95-3.59 for NYHA class III/IV; p-interaction = 0.062), mostly driven by the LVEF <40% subgroup.
1 context sentence(design, population, supporting numbers)
Summary · context
Post-hoc analysis of the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial evaluating the effects of once-weekly exenatide (EQW) versus placebo on cardiovascular outcomes according to baseline LVEF (<40% or ≥40%).
Report a problemFND-3938195008
09HumanOther designEfficacy outcome
In T2D, the reported NYHA interaction for exenatide versus placebo on HHF had p-interaction = 0.062.
In plain wordsIn T2D, the NYHA interaction test for exenatide versus placebo on heart failure hospitalization had P = 0.062.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedNYHA interaction for heart failure hospitalization
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
once weeklyAs given in this study (human).
Measurements
p-interaction
0.062 p-value
treatment-by-NYHA class interaction for HHF
Source sentences
Summary
The risk of HHF was also modified by baseline NYHA class (HR 0.91, 95% CI 0.65-1.27 for NYHA class I/II; HR 1.84, 95% CI 0.95-3.59 for NYHA class III/IV; p-interaction = 0.062), mostly driven by the LVEF <40% subgroup.
1 context sentence(design, population, supporting numbers)
Summary · context
Post-hoc analysis of the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial evaluating the effects of once-weekly exenatide (EQW) versus placebo on cardiovascular outcomes according to baseline LVEF (<40% or ≥40%).
Report a problemFND-3938195009
10HumanOther designEfficacy outcome
In T2D, obesity did not modify the exenatide effect on HHF versus placebo.
In plain wordsIn T2D, exenatide's effect on heart failure hospitalization versus placebo did not differ by obesity.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeObesity interaction for heart failure hospitalization
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
once weeklyAs given in this study (human).
Source sentences
Summary
Obesity did not modify the effects of EQW on HHF.
1 context sentence(design, population, supporting numbers)
Summary · context
Post-hoc analysis of the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial evaluating the effects of once-weekly exenatide (EQW) versus placebo on cardiovascular outcomes according to baseline LVEF (<40% or ≥40%).
Report a problemFND-3938195010

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.

Summary

Results from this study10

Version history

Subjects

Publication types

MeSH terms

Keywords